In conclusion, the results of the present study demonstrate that DHMEQ has a beneficial effect on pristane-induced lupus through regulating cytokine levels and the MAPK/JNK/NF-κB signaling pathway. Here, NFKB1 is linked to systemic lupus erythematosus.